Synageva BioPharma Corp. (NASDAQ:GEVA)

CAPS Rating: 1 out of 5

Results 1 - 2 of 2

Recs

1
Member Avatar zzlangerhans (99.85) Submitted: 1/2/2015 3:25:24 PM : Underperform Start Price: $94.21 GEVA Score: -25.01

Why not take a smack at two Baker Bros stocks on the same day? Synageva has been a volatile stock over the past two years as enthusiasm over their orphan drug candidate and Baker Bros involvement has alternated with skepticism about the size of the market for their enzyme replacement therapy. Since I've still never heard of the disease they are treating outside of my research on the stock, count me among the skeptics when the market cap gets over three billion. On the other hand, don't expect the share price to plunge any time soon when there are regulatory applications for sebelipase alfa under review in both the US and EU and the Bakers are continuing to hold fast.

Recs

1
Member Avatar IBDContrarian (22.64) Submitted: 7/23/2012 1:45:33 PM : Underperform Start Price: $49.14 GEVA Score: -86.61

IBD EPS, RS, SPROE, Acc ratings plus P/E and div yield
MED 3 99 ..A NEG

Name: SyngvBioPh

Results 1 - 2 of 2

Featured Broker Partners


Advertisement